Evidence map›Paper›PMID 22578383›Full record

ArticleMolecular immunology2012

Role of microRNA-15a in autoantibody production in interferon-augmented murine model of lupus.

Yao Yuan, Siddha Kasar, Chingiz Underbayev, Daniel Vollenweider, Erica Salerno, Sergei V Kotenko, Elizabeth Raveche

Open access · greenAbstract read
In one paragraph

Article in Molecular immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 49 citations in OpenAlex.

  1. Review
  2. Review
  3. Cytokines and microRNAs in SARS-CoV-2: What do we know?Molecular therapy. Nucleic acids · 2022
    Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. MicroRNAs in autoimmune diseases.BioMed research international · 2014
    Review
  18. Review
  19. Review
  20. IFNα Inducible Models of Murine SLE.Frontiers in immunology · 2013
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yao YuanPathology and Laboratory Medicine, New Jersey Medical School, MSB C512, 185 S. Orange Avenue, Newark, NJ 07103, United States.
Siddha Kasar
Chingiz Underbayev
Daniel Vollenweider
Erica Salerno
Sergei V Kotenko
Elizabeth Raveche
Rutgers New Jersey Medical SchoolRutgers, The State University of New Jersey · US

Funding

Studies of the role of microRNA miR-16-1 in the NZB mouse model of CLLR01CA129826 · NCI · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI RAVECHE, ELIZABETH S · 2010 to 2012
$938k
NCI NIH HHS R01 CA129826NCI NIH HHS R01CA129826
6 · The paper itself

Abstract

MicroRNAs (miRNAs) are involved in the regulation of immunity via targeting of mRNA encoding immune response elements. In this report, alterations in the expression of microRNAs as autoantibody levels increase was investigated. The (NZB×NZW)F1 or B/W mouse model of systemic lupus erythematosus (SLE) naturally has increased autoantibodies with aging. IFNα (type I IFN) accelerates B/W disease, however, the effects of a related IFN, IFNλ, which is a type III IFN, is largely unknown. The purpose of the study was to investigate the relationship between IFN-accelerated disease, microRNAs, immunoregulatory B cell subsets and autoantibody production in the autoimmune-prone environment in vivo. B/W mice received osmotic pumps to chronically deliver IFNα and IFNλ for up to 16 weeks. Urine protein level was monitored weekly by urine strips and proteinuria was used as the disease marker. Splenic cells were taken for flow analysis of B cell subsets and levels of microRNAs determined. Plasma were analyzed for autoantibodies and microRNA levels. As a result of treatment, IFNα accelerated proteinuria in a dose dependent manner, while IFNλ single treatment did not show a significant effect, but greatly enhanced low dose IFNα effects in the combination treatment. Both the splenic cellular and plasma miR-15a were elevated in diseased compared to pre-diseased mice as well as autoantibody levels. Autoantibodies and miR-15a levels were significantly correlated. The immunosuppressive B subpopulation, B-10, was reduced following IFNα treatment. In addition in diseased mice, B-10 versus B-2 ratios were reduced in IFN-treated B/W compared to the control PBS treated group. In all B/W the miR-15a was highly expressed in the B-10 subset and this increased with disease development, suggesting that miR-15a has a specific negative effect on the B-10 subpopulation. In conclusion, our data support the involvement of elevated miR-15a in autoimmune disease development in B/W mice and suggest that decreasing this microRNA might be beneficial in B/W mice.

Indexed as

AnimalsAutoantibodiesBase SequenceB-Lymphocyte SubsetsDisease Models, AnimalDNA PrimersFemaleInterferon-alphaInterferonsLupus Erythematosus, SystemicMiceMice, Inbred NZBMicroRNAsRecombinant ProteinsSpleenUp-RegulationAutoantibodiesDNA PrimersInterferon-alphaInterferonsMicroRNAsMirn15a microRNA, mouseRecombinant Proteins

Identifiers

PMID22578383
PMCPMC3865977
OpenAlexW1981469954

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.